Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) said, “We continue to enroll patients in each of our three clinical trials as expected, and as planned for. By the end of 2014, we expect to achieve key milestones in each trial. In Q4 we expect to have data from our Phase I trial of Supinoxin in cancer patients with solid tumors. We are also scheduled to complete enrollment of patients in our Phase Ib clinical trial of RX-3117 by the end of 2014. During Q4 of this year, we anticipate completing the safety portion of our Phase II trial for metastatic renal cell carcinoma.” Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock performance was 19.21% in last session and finished the day at $1.03. Traded volume was 15,597,200 shares in the last session and the average volume of the stock remained 6.30 million shares. The beta of the stock remained 1.41. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) insider ownership is 4.20%.

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co (NYSE:LLY) announced. Additionally, similar proportions of patients in the linagliptin and placebo groups experienced adverse events, including the incidence of investigator-reported hypoglycemia. These data were presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific & Clinical Congress in Las Vegas. Eli Lilly and Co (NYSE:LLY) dropped -3.14% to $58.21 yesterday on volume of 9,765,000 shares. The intra-day range of the stock was $58.01 – 59.81. Eli Lilly and Co (NYSE:LLY) has a market capitalization of $65.16 billion.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that clinical data on Iclusig (R) (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on May 15, 2014 reported a decrease of -2.26% to the closing price of $6.50. Its fifty two weeks range is $2.15 – 23.00. The total market capitalization recorded $1.21 billion. The overall volume in the last trading session was 6,916,600 shares. In its share capital, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has 186.79 outstanding shares.

The leading producer and developer of therapeutic products, MannKind Corporation (NASDAQ:MNKD) has excelled in developing a range of new products. The products are designed to provide relief from critical ailments and are gaining momentum in the market. MannKind has announced its quarterly results for analyzing its investments and growth to shape its strategy for coming quarters. Recently, MannKind Corporation (NASDAQ:MNKD) has launched its latest product called as AFREZZA. It is essentially an insulin inhaler that is designed to deliver Type 1 and Type 2 insulin to the diabetic patients. AFREZZA has potential to replace insulin injections in the near future. MannKind has recently completed its clinical trials. The data has been forwarded to FDA Advisory Panel in April and is scheduled to be reviewed on July 15, 2014. On Thursday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -1.14% to close the day at $6.93. Company monthly performance is recorded as 10.35%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 22.01%.

Home health and hospice services provider Gentiva Health Services, Inc. (NASDAQ:GTIV) board on Thursday rejected a unsolicited, non-binding $533 million cash and stock acquisition offer from healthcare services provider Kindred Healthcare, Inc. (KND: Quote), saying the offer undervalues the company. Atlanta, Georgia-based Gentiva said its board has thoroughly evaluated the successive, non-binding proposals of April 14 and May 5 made to its executive chairman and CEO. On Thursday, shares of Gentiva Health Services, Inc. (NASDAQ:GTIV) advanced 61.94% to close the day at $13.83. Company return on investment (ROI) is -69.10% and its monthly performance is recorded as 81.50%. Gentiva Health Services, Inc. (NASDAQ:GTIV) quarterly revenue growth is 26.76%.